Fawzi Abu Rous, MD

Thoracic Medical Oncologist @HenryFordHealth | Co-host @LungCancerRx | Alum @HFHemOncFellows @MSU_Medicine @UJ_MED | Girl Dad | Opinions = Own

[Fawzi Abu Rous, MD @FawziAbuRous]

Ending 2024 on a high note! Honored to receive a $310K grant from the #UCanCerVive Foundation to continue my research on squamous cell carcinoma of the lung. Immense gratitude to the @LaFontaineAuto family for supporting #Michigan researchers and to @ShirishGadgeel @NallasivamPala4 for their unwavering support
#lcsm #biomarkers

[Eric K. Singhi, MD @lungoncdoc]

‼️Houston oncology colleagues: Join us for an interactive evening discussing what’s changing in lung cancer, from frontline EGFR-mutant NSCLC to ADCs, SCLC, and real-world practice. Bring your toughest questions!

Register here: https://t.co/6ntqe5L9Hi

[Eric K. Singhi, MD @lungoncdoc]

Our @UTMDAnderson pre-visit liquid biopsy #LUNGFAST pilot is now published in @ClinicalLung!

▫️94% of eligible pts identified early by nurse navigators
▫️45% had actionable/clinically relevant alterations
▫️22% had meaningful alterations on liquid bx

https://t.co/3ftXmaVG3X

[LungCancerRx 🫁💊 @LungCancerRx]

NEW episode of #LungCancerRx is out!

Expert guest @FSkoulidis breaks down KRAS, STK11, and KEAP1 mutant NSCLC.

@ADesaiMD @FawziAbuRous @lungoncdoc @OncNewsCentral

https://t.co/rGfG2xLnAF

[Chinmay Jani @Jani_Chinmay]

🎉 My first ASCO committee meeting was with the Stage IV NSCLC Guidelines Committee!

It was truly an honor to learn from experts helping shape evidence-based care for patients with lung cancer.

Grateful for the opportunity and looking forward to contributing, learning, and growing through this experience.
#ASCO26 #LungCancer #NSCLC #Oncology @SylvesterCancer

[Laura Alder, MD @LauraAlderMD]

New in @JThoracOncol:
📌 Compound (PACC/PACC AND PACC/classical) mutations both show enhanced sensitivity to 2nd-gen TKIs (afatinib) over osimertinib in 1L
📌 PACC pts on 1L osimertinib trended toward shorter ToT vs classical (19.5 vs 28.5 mo)
🧬 Bottom line: When you see a compound mutation with a PACC component (G719X, S768I, E709X) — even if paired with L858R or Ex19del — treat it as PACC. Consider 2nd-gen TKIs over osimertinib.
⭐️Still an area of unmet need! Novel agents like firmonertinib, silevertinib enozertinib are being studied.
Great effort by @LeXiuning and team!
https://t.co/u6tMuVNXrP

[Tejas Patil @TejasPatilMD]

Whoa, this is such a helpful tool!!!

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

#ASCO26 #ANVIL is in.
➡️Adjuvant nivolumab: negative.

DFS HR 0.97, p=0.78. N=935.
6 years of follow-up. PD-L1≥50%: HR 0.86, p=0.43.

But here's what makes this problematic; put it next to IMpower010 and KEYNOTE-091:
PD-L1≥50%:
• IMpower010 (atezo): HR 0.43 ✓
• KEYNOTE-091 (pembro): HR 0.82 ✗
• ANVIL (nivo): HR 0.86 ✗

PD-L1<1%:
• IMpower010: HR 0.97 ✗
• KEYNOTE-091: HR 0.75 ✓
• ANVIL: HR 0.97 ✗

Three drugs. Three assays. Completely inconsistent results by PD-L1 subgroup. No reproducible biomarker-efficacy relationship across trials.

I do not think this is a nivolumab problem. It's an adjuvant IO problem. We don't understand which patients benefit and after 3 phase IIIs, we still can't reliably select them. ctDNA-guided adjuvant therapy can't come fast enough.
@ASCO @LungCancerRx

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

Just finished recording another incredible conversation with @ajuloorimd and @FawziAbuRous for @LungCancerRx! @lungoncdoc
Can't wait to share it with you all, stay tuned.
https://t.co/qSmHiboJMI #RiversideFM

[LungCancerRx 🫁💊 @LungCancerRx]

NEW episode alert!

@FordePatrick joins us to break down what’s actually changing in early-stage resectable NSCLC, from neoadjuvant to perioperative strategies, and how it’s reshaping real-world decisions.

Full episode here: https://t.co/e6ytwK7U3e

[Fawzi Abu Rous, MD @FawziAbuRous]

@Charbel_matar1 @GlopesMd @GWCancer @GWtweets Congratulations 👏🏼👏🏼👏🏼

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🧬 My Top 10 DT abstracts at #ASCO2026
3 storylines I'm watching:
→ KRAS G12D: noncovalent DN022150 (Ph I/IIa) + RNK08954 (Ph II) in parallel
→ Macrocyclic EGFR arrives: BH-30643 FIH
→ Radioligand enters SCLC: 177Lu-DOTA-TATE in #SCLC
@OncoAlert @oncodaily @Larvol

[OncoDaily Lung @OncodailyLung]

Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC - Fawzi Abu Rous

@FawziAbuRous @YoungLungCancer @RevMedicines

https://t.co/9GdEONWUPM

#OncoDaily #Oncology #Cancer #Health #Medicine #LungCancer #MedX #MedTwitter #NSCLC

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO

From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming.

Which one are you watching?

@OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

[Young Lung Cancer Initiative @YoungLungCancer]

For decades, KRAS was considered "undruggable." Here's why that changed &amp; what it means for lung cancer patients

Full 3 part series w/ Dr. @FawziAbuRous on YouTube: https://t.co/01AUm2eRkN

Thank you to @RevMedicines for sponsoring

YLCI retains editorial control over content

[Abhinav Vyas, MD @vyasabhinav2]

Excited to share our latest review on evolving treatment strategies in EGFR-mutated NSCLC - spanning early-stage to metastatic disease. https://t.co/AvAbSCOupr. Thank you Dr. Desai for this opportunity. @ADesaiMD @ONealCancerUA @LLUHealth @MOASC_Office @LLUMedSchool #oncology

[Fawzi Abu Rous, MD @FawziAbuRous]

@DipeshUpretyMD @abhinav_deol @UMGCCC Congratulations Dipesh! Very well deserved 👏🏼

[OncoDaily @oncodaily]

Final Call for the Detroit 2026 Hematology and Oncology Practice Symposium - @FawziAbuRous

@binaytara @MariaDiab101

https://t.co/sg5iphgN7V

#Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

[OncoDaily @oncodaily]

Excited To Welcome Dr. Fawzi Abu Rous, MD To OHCI Orlando Health Grand Rounds - Jad Chahoud

@JadChahoud @OrlandoHealt @FawziAbuRous

https://t.co/D0ZPMqJXV1

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

[Fawzi Abu Rous, MD @FawziAbuRous]

Register today for this high-impact CME/CE-accredited symposium, hosted by the @binaytara Foundation and co-chaired by Dr. @MariaDiab101 and myself.

This year’s program brings together leading experts from across Michigan, with @PTarantinoMD joining us as our keynote speaker.

Looking forward to an outstanding day of learning and collaboration on April 18 — hope to see you there!

#Oncology #CME #MedicalEducation #Michigan #CancerCare #BinaytaraFoundation
@oncodaily @HFHemOncFellows @HenryFordHealth

[Binaytara @binaytara]

Final Call! The CME/CE-accredited Detroit 2026 Hematology and Oncology Practice Symposium is just around the corner! Led by Drs. @FawziAbuRous and @MariaDiab101 , this interactive symposium will deliver practice-changing insights across lung, GI, GU, breast, and hematologic cancers—along with a keynote on the evolving role of antibody-drug conjugates. Register NOW: https://t.co/hEa94FGekh #CMEConference #Oncology #Hematology #CancerCare #Binaytara #HemOnc #MedTwiiter #MedX

[Eric K. Singhi, MD @lungoncdoc]

When (&amp; for whom) should we “go beyond” systemic therapy in stage IV NSCLC?

Our patient-friendly @JAMAOnc publication reviews LCT patient selection + clinical context.

🔗 https://t.co/4q3x431bkY

Rule of 3: Right patient. Right time. Right team.

@maraantonoff @UTMDAnderson